Literature DB >> 27377864

Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors.

Florence F Wagner1, Michel Weïwer2, Stefan Steinbacher3, Adrian Schomburg3, Peter Reinemer3, Jennifer P Gale2, Arthur J Campbell2, Stewart L Fisher4, Wen-Ning Zhao5, Surya A Reis5, Krista M Hennig5, Méryl Thomas2, Peter Müller6, Martin R Jefson7, Daniel M Fass5, Stephen J Haggarty5, Yan-Ling Zhang2, Edward B Holson8.   

Abstract

The structure-activity and structure-kinetic relationships of a series of novel and selective ortho-aminoanilide inhibitors of histone deacetylases (HDACs) 1 and 2 are described. Different kinetic and thermodynamic selectivity profiles were obtained by varying the moiety occupying an 11Å channel leading to the Zn(2+) catalytic pocket of HDACs 1 and 2, two paralogs with a high degree of structural similarity. The design of these novel inhibitors was informed by two ligand-bound crystal structures of truncated hHDAC2. BRD4884 and BRD7232 possess kinetic selectivity for HDAC1 versus HDAC2. We demonstrate that the binding kinetics of HDAC inhibitors can be tuned for individual isoforms in order to modulate target residence time while retaining functional activity and increased histone H4K12 and H3K9 acetylation in primary mouse neuronal cell culture assays. These chromatin modifiers, with tuned binding kinetic profiles, can be used to define the relation between target engagement requirements and the pharmacodynamic response of HDACs in different disease applications.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acetylation; HDAC inhibitors; Isoform selectivity; Kinetic selectivity; Target engagement

Mesh:

Substances:

Year:  2016        PMID: 27377864     DOI: 10.1016/j.bmc.2016.06.040

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  16 in total

1.  Selectivity and Kinetic Requirements of HDAC Inhibitors as Progranulin Enhancers for Treating Frontotemporal Dementia.

Authors:  Angela She; Iren Kurtser; Surya A Reis; Krista Hennig; Jenny Lai; Audrey Lang; Wen-Ning Zhao; Ralph Mazitschek; Bradford C Dickerson; Joachim Herz; Stephen J Haggarty
Journal:  Cell Chem Biol       Date:  2017-07-14       Impact factor: 8.116

Review 2.  The nonepigenetic role for small molecule histone deacetylase inhibitors in the regulation of cardiac function.

Authors:  Samantha S Romanick; Bradley S Ferguson
Journal:  Future Med Chem       Date:  2019-06-04       Impact factor: 3.808

3.  Kinetic Tuning of HDAC Inhibitors Affords Potent Inducers of Progranulin Expression.

Authors:  Carlos Moreno-Yruela; Daniel M Fass; Chialin Cheng; Joachim Herz; Christian A Olsen; Stephen J Haggarty
Journal:  ACS Chem Neurosci       Date:  2019-08-05       Impact factor: 4.418

4.  Development of Pyrazine-Anilinobenzamides as Histone Deacetylase HDAC1-3 Selective Inhibitors and Biological Testing Against Pancreas Cancer Cell Lines.

Authors:  Mohamed Abdelsalam; Hany S Ibrahim; Lukas Krauss; Matthes Zessin; Anita Vecchio; Sieglinde Hastreiter; Mike Schutkowski; Günter Schneider; Wolfgang Sippl
Journal:  Methods Mol Biol       Date:  2023

5.  Docking, Binding Free Energy Calculations and In Vitro Characterization of Pyrazine Linked 2-Aminobenzamides as Novel Class I Histone Deacetylase (HDAC) Inhibitors.

Authors:  Emre F Bülbül; Jelena Melesina; Hany S Ibrahim; Mohamed Abdelsalam; Anita Vecchio; Dina Robaa; Matthes Zessin; Mike Schutkowski; Wolfgang Sippl
Journal:  Molecules       Date:  2022-04-14       Impact factor: 4.411

Review 6.  The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors.

Authors:  Fangyuan Cao; Martijn R H Zwinderman; Frank J Dekker
Journal:  Molecules       Date:  2018-03-02       Impact factor: 4.411

Review 7.  Food Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart Failure.

Authors:  Levi W Evans; Bradley S Ferguson
Journal:  Nutrients       Date:  2018-08-18       Impact factor: 5.717

8.  CoREST Complex-Selective Histone Deacetylase Inhibitors Show Prosynaptic Effects and an Improved Safety Profile To Enable Treatment of Synaptopathies.

Authors:  Nathan O Fuller; Antonella Pirone; Berkley A Lynch; Michael C Hewitt; Maria S Quinton; Timothy D McKee; Magnus Ivarsson
Journal:  ACS Chem Neurosci       Date:  2018-12-13       Impact factor: 4.418

Review 9.  The critical roles of histone deacetylase 3 in the pathogenesis of solid organ injury.

Authors:  Li Ning; Xiong Rui; Wang Bo; Geng Qing
Journal:  Cell Death Dis       Date:  2021-07-23       Impact factor: 8.469

10.  Lysine-14 acetylation of histone H3 in chromatin confers resistance to the deacetylase and demethylase activities of an epigenetic silencing complex.

Authors:  Mingxuan Wu; Dawn Hayward; Jay H Kalin; Yun Song; John Wr Schwabe; Philip A Cole
Journal:  Elife       Date:  2018-06-05       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.